CY1108833T1 - Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης - Google Patents

Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης

Info

Publication number
CY1108833T1
CY1108833T1 CY20091100233T CY091100233T CY1108833T1 CY 1108833 T1 CY1108833 T1 CY 1108833T1 CY 20091100233 T CY20091100233 T CY 20091100233T CY 091100233 T CY091100233 T CY 091100233T CY 1108833 T1 CY1108833 T1 CY 1108833T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical
solid pressure
solutions
pressure inhibition
stable
Prior art date
Application number
CY20091100233T
Other languages
Greek (el)
English (en)
Inventor
David Lewis
David Ganderton
Brian Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8163952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108833(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1108833T1 publication Critical patent/CY1108833T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20091100233T 2000-05-22 2009-02-27 Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης CY1108833T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2000/004635 WO2001089480A1 (en) 2000-05-22 2000-05-22 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
EP04011423A EP1466594B1 (en) 2000-05-22 2001-05-18 Stable pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (1)

Publication Number Publication Date
CY1108833T1 true CY1108833T1 (el) 2014-07-02

Family

ID=8163952

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20091100233T CY1108833T1 (el) 2000-05-22 2009-02-27 Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY20091100391T CY1108968T1 (el) 2000-05-22 2009-04-03 Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY2009009C CY2009009I1 (el) 2000-05-22 2009-07-03 Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY20111100584T CY1111570T1 (el) 2000-05-22 2011-06-20 Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY2011014C CY2011014I2 (el) 2000-05-22 2011-09-22 Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY20121100369T CY1113028T1 (el) 2000-05-22 2012-04-18 Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης

Family Applications After (5)

Application Number Title Priority Date Filing Date
CY20091100391T CY1108968T1 (el) 2000-05-22 2009-04-03 Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY2009009C CY2009009I1 (el) 2000-05-22 2009-07-03 Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY20111100584T CY1111570T1 (el) 2000-05-22 2011-06-20 Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY2011014C CY2011014I2 (el) 2000-05-22 2011-09-22 Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
CY20121100369T CY1113028T1 (el) 2000-05-22 2012-04-18 Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης

Country Status (40)

Country Link
US (3) US6716414B2 (instruction)
EP (4) EP1787639B1 (instruction)
JP (1) JP5392880B2 (instruction)
CN (1) CN1213732C (instruction)
AR (1) AR029523A1 (instruction)
AT (4) ATE419832T1 (instruction)
AU (2) AU5070100A (instruction)
BE (1) BE2011C032I2 (instruction)
BG (1) BG65883B1 (instruction)
BR (1) BR0015884A (instruction)
CA (1) CA2411047C (instruction)
CY (6) CY1108833T1 (instruction)
CZ (1) CZ303833B6 (instruction)
DE (5) DE60136864D1 (instruction)
DK (4) DK1787639T3 (instruction)
DZ (1) DZ3358A1 (instruction)
EA (1) EA005179B1 (instruction)
EE (1) EE05167B1 (instruction)
ES (4) ES2380790T3 (instruction)
FR (1) FR11C0041I2 (instruction)
HR (1) HRP20021025B1 (instruction)
HU (2) HU230804B1 (instruction)
IL (2) IL152955A0 (instruction)
JO (1) JO2310B1 (instruction)
LT (1) LTC1787639I2 (instruction)
LU (1) LU91875I2 (instruction)
ME (2) ME00220B (instruction)
MX (1) MXPA02011414A (instruction)
MY (2) MY143733A (instruction)
NL (1) NL300393I2 (instruction)
NO (3) NO342935B1 (instruction)
PE (1) PE20011323A1 (instruction)
PT (4) PT1157689E (instruction)
SA (1) SA01220126B1 (instruction)
SI (4) SI1787639T1 (instruction)
SK (1) SK286694B6 (instruction)
TN (1) TNSN01074A1 (instruction)
TW (1) TWI284047B (instruction)
UA (1) UA73986C2 (instruction)
WO (1) WO2001089480A1 (instruction)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
AU1534501A (en) * 1999-11-23 2001-06-04 Glaxo Group Limited Pharmaceutical formulations of salmeterol
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
HUP0302005A3 (en) * 2000-05-23 2006-07-28 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
EP1372608B1 (de) * 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
PT1273292E (pt) 2001-07-02 2004-10-29 Chiesi Farma Spa Formulacao optimizada de tobramicina para aerossolizacao
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
SI3536344T1 (sl) * 2002-03-01 2020-06-30 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
US20040166065A1 (en) 2002-08-14 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation comprising an anticholinergic
PL375511A1 (en) * 2002-08-14 2005-11-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Aerosol formulation for inhalation containing an anticholinergic agent
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20050003024A1 (en) * 2003-03-04 2005-01-06 The Procter & Gamble Company Regulation of mammalian hair growth
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
NZ545442A (en) * 2003-07-29 2010-05-28 Boehringer Ingelheim Int Medicaments for inhalation comprising betamimetics and an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-l-azoniabicyclo[2.2.2]octane
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
EP1654001A2 (en) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising steroids and a betamimetic
BRPI0414428A (pt) * 2003-09-15 2006-11-14 Vectura Ltd composições farmacêuticas
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
KR20070000476A (ko) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. 압축화 계량된 도스흡입용 안정된 약제용액 제제
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
UA88894C2 (ru) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением
KR20070010159A (ko) * 2004-05-13 2007-01-22 키에시 파르마슈티시 엣스. 피. 에이. 화학안정성이 향상된 약제 에어로졸 제제 생성물
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
CN101119706B (zh) * 2005-02-25 2013-04-17 奇斯药制品公司 用于加压计量吸入器的包含螯合剂的药物气雾制剂
JP2008534611A (ja) * 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
DE102005055960A1 (de) * 2005-11-24 2007-07-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
GB0613761D0 (en) * 2006-07-11 2006-08-23 Norton Healthcare Ltd A pharmaceutical formulation and method for the preparation thereof
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US20090208424A1 (en) * 2008-02-19 2009-08-20 Todd Maibach Compositions and methods for delivery of solution to the skin
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20110250242A1 (en) * 2008-10-23 2011-10-13 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
EP2201934A1 (en) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
PL2727582T3 (pl) * 2009-10-02 2016-06-30 Chiesi Farm Spa Farmaceutyczne formulacje aerozolowe formoterolu i dipropionianu beklometazonu
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5715640B2 (ja) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
ES2468835T3 (es) 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
SG181868A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Combination therapy for copd
EP2515854B1 (en) 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Aerosol formualtion for COPD
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012010854A1 (en) 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
GB201200504D0 (en) * 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
PL3089735T3 (pl) * 2013-12-30 2018-12-31 Chiesi Farmaceutici S.P.A. Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu
GEP20186870B (en) * 2013-12-30 2018-06-25 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
DK3139984T3 (da) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Forstøver
CN106255554B (zh) 2014-05-07 2021-05-04 勃林格殷格翰国际有限公司 容器、喷雾器及用途
PT3139982T (pt) 2014-05-07 2022-04-05 Boehringer Ingelheim Int Nebulizador
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
CN104225739A (zh) * 2014-09-30 2014-12-24 四川普锐特医药科技有限责任公司 一种医用定量吸入气雾剂
CN108289843B (zh) 2015-12-04 2021-08-17 墨西哥氟石股份公司 药物组合物
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
EP3634459A4 (en) 2017-02-10 2021-01-06 Washington University ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE
JOP20200314A1 (ar) 2018-06-04 2020-12-06 Lupin Inc تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
NZ786610A (en) 2019-12-02 2025-06-27 Chiesi Farm Spa Stainless steel can for pressurised metered dose inhalers
GB2593283B (en) 2020-01-28 2023-09-13 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
PE20230236A1 (es) 2020-02-20 2023-02-07 Chiesi Farm Spa Inhaladores dosificadores presurizados que comprenden una formulacion farmaceutica amortiguada
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11642372B2 (en) * 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
BR112023001689A2 (pt) 2020-07-31 2023-05-02 Chemo Res S L Terapia de combinação para administração por inalação
CA3193038A1 (en) * 2020-10-09 2022-04-14 Enrico Zambelli A pharmaceutical formulation for pressurised metered dose inhaler
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations
EP4504338A1 (en) 2022-04-06 2025-02-12 RAPT Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN119630425A (zh) 2022-05-27 2025-03-14 奇斯药制品公司 用于加压定量吸入器的药物制剂
CN119255820A (zh) 2022-05-27 2025-01-03 奇斯药制品公司 用于加压定量吸入器的药物制剂

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
KR930703251A (ko) 1990-12-19 1993-11-29 스튜어트 알. 슈터 에어로졸 제제
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ATE171630T1 (de) 1991-05-21 1998-10-15 Abbott Lab Aerosolinhalationsvorrichtung
US5435297A (en) 1991-08-29 1995-07-25 Christoph Klein Medical device for inhaling metered aerosols
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
DK1086688T3 (da) * 1991-12-18 2004-08-16 Minnesota Mining & Mfg Aerosolformuleringer til suspensioner
DE4230876A1 (de) 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
DE69324161T2 (de) 1992-12-09 1999-10-28 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield Stabilisierte medizinische aerosollösungen
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
AU4066693A (en) 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
KR100321650B1 (ko) * 1993-03-17 2002-07-27 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 디올/디산계분산보조제를함유하는분무제제
AU679511B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
EP0806940B1 (en) * 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
EP1870122A3 (en) 1995-04-14 2008-03-12 SmithKline Beecham Corporation Metered dose inhaler
EP0820322B1 (en) 1995-04-14 2002-07-10 SmithKline Beecham Corporation Metered dose inhaler for fluticasone propionate
ATE258813T1 (de) 1995-04-14 2004-02-15 Smithkline Beecham Corp Vorrichtung zur dosierten inhalierung von beclomethason-diproprionat
CA2217954C (en) 1995-04-14 2005-02-15 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
US6135628A (en) * 1995-10-13 2000-10-24 Boehringer Ingelheim Pharmceuticals, Inc. Method and apparatus for homogenizing aerosol formulations
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
JP2000514085A (ja) 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
WO1998003533A1 (en) 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
CA2273835A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
AU718967B2 (en) 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6000537A (en) * 1997-06-10 1999-12-14 U.S. Philips Corporation Housing with readable side walls for a disc-shaped information carrier
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6324827B1 (en) * 1997-07-01 2001-12-04 Bp Corporation North America Inc. Method of generating power in a dry low NOx combustion system
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
AU2081999A (en) * 1998-01-13 1999-08-02 Astrazeneca Uk Limited Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
CZ300910B6 (cs) * 1998-06-18 2009-09-09 Boehringer Ingelheim Pharmaceuticals, Inc. Farmaceutický prostredek
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000006121A1 (de) * 1998-07-24 2000-02-10 Jago Research Ag Medizinische aerosolformulierungen
NZ509489A (en) * 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DE19847969A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
HK1041448B (zh) * 1998-10-17 2005-05-13 贝林格尔英格海姆法玛两合公司 可儲存的含福莫特羅的活性物質濃縮液
DE59904488D1 (de) 1998-11-13 2003-04-10 Jago Res Ag Muttenz Trockenpulver zur inhalation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
ES2286881T3 (es) 1999-03-05 2007-12-01 Chiesi Farmaceutici S.P.A. Composiciones farmaceuticas en polvo mejoradas para inhalacion.
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
JP2003518484A (ja) 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
SI3536344T1 (sl) * 2002-03-01 2020-06-30 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
HUP0302007A3 (en) 2006-07-28
DK1466594T3 (da) 2009-03-02
CY2011014I1 (el) 2015-10-07
AU2000250701B2 (en) 2004-07-01
BG65883B1 (bg) 2010-04-30
SI1157689T1 (sl) 2009-06-30
FR11C0041I2 (fr) 2015-09-04
AU5070100A (en) 2001-12-03
NO342935B1 (no) 2018-09-03
EP1787639B1 (en) 2011-03-23
BG107256A (bg) 2003-06-30
HU230804B1 (hu) 2018-06-28
ATE419832T1 (de) 2009-01-15
JP2003534266A (ja) 2003-11-18
CY2011014I2 (el) 2015-10-07
ATE502624T1 (de) 2011-04-15
EP2223682B1 (en) 2012-01-18
BR0015884A (pt) 2003-07-08
SK286694B6 (sk) 2009-03-05
MY127145A (en) 2006-11-30
PE20011323A1 (es) 2002-01-22
CY1108968T1 (el) 2014-04-09
DE122011100049I1 (de) 2012-01-19
CY2009009I2 (el) 2014-04-09
US7018618B2 (en) 2006-03-28
DE60137282D1 (de) 2009-02-26
IL152955A (en) 2010-02-17
NO2019003I1 (no) 2019-01-16
TNSN01074A1 (fr) 2005-11-10
HK1058900A1 (en) 2004-06-11
AR029523A1 (es) 2003-07-02
NL300393I2 (en) 2010-02-01
ATE415945T1 (de) 2008-12-15
EP1157689A1 (en) 2001-11-28
NO20025568L (no) 2002-11-20
DZ3358A1 (fr) 2001-11-29
EP1157689B1 (en) 2009-01-07
ES2380790T3 (es) 2012-05-18
EP1466594B1 (en) 2008-12-03
FR11C0041I1 (instruction) 2011-04-11
EA200201058A1 (ru) 2003-04-24
CY1111570T1 (el) 2015-10-07
SI1466594T1 (sl) 2009-06-30
CA2411047A1 (en) 2001-11-29
EP1466594A2 (en) 2004-10-13
ATE541563T1 (de) 2012-02-15
NL300393I1 (en) 2009-09-01
CZ20023835A3 (cs) 2003-04-16
BE2011C032I2 (instruction) 2020-08-20
JP5392880B2 (ja) 2014-01-22
DE122009000035I1 (de) 2009-11-05
DE60136864D1 (de) 2009-01-15
US20060083693A1 (en) 2006-04-20
PT2223682E (pt) 2012-03-22
LU91875I2 (fr) 2011-11-21
IL152955A0 (en) 2003-06-24
WO2001089480A1 (en) 2001-11-29
LTPA2011011I1 (lt) 2019-08-26
EP1787639A2 (en) 2007-05-23
DE60144304D1 (de) 2011-05-05
SI1787639T1 (sl) 2011-07-29
US6716414B2 (en) 2004-04-06
US20040047809A1 (en) 2004-03-11
EE05167B1 (et) 2009-06-15
HRP20021025B1 (hr) 2013-11-22
SK16522002A3 (sk) 2003-04-01
EE200200649A (et) 2004-06-15
CN1213732C (zh) 2005-08-10
CA2411047C (en) 2009-08-04
AU2000250701A1 (en) 2002-02-21
CY1113028T1 (el) 2016-04-13
EP1466594A3 (en) 2004-12-01
HRP20021025A2 (en) 2004-02-29
DK1157689T3 (da) 2009-03-16
HUS1800032I1 (hu) 2018-08-28
PT1787639E (pt) 2011-06-08
SI2223682T1 (sl) 2012-04-30
ES2359991T3 (es) 2011-05-30
LTC1787639I2 (lt) 2021-05-25
CN1452479A (zh) 2003-10-29
JO2310B1 (en) 2005-09-12
ES2318217T3 (es) 2009-05-01
DK1787639T3 (da) 2011-05-09
MXPA02011414A (es) 2003-06-06
SA01220126B1 (ar) 2007-04-03
EP1787639A3 (en) 2009-02-25
TWI284047B (en) 2007-07-21
US20020025299A1 (en) 2002-02-28
UA73986C2 (uk) 2005-10-17
DK2223682T3 (da) 2012-03-19
MY143733A (en) 2011-07-15
EP2223682A1 (en) 2010-09-01
PT1157689E (pt) 2009-03-23
ME00220B (me) 2010-10-10
CZ303833B6 (cs) 2013-05-22
PL359149A1 (en) 2004-08-23
NO20025568D0 (no) 2002-11-20
PT1466594E (pt) 2009-02-13
NO2019030I1 (no) 2019-07-11
HUP0302007A2 (hu) 2003-09-29
MEP32108A (en) 2010-10-10
CY2009009I1 (el) 2014-04-09
ES2320194T3 (es) 2009-05-20
EA005179B1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
CY1108833T1 (el) Σταθερες φαρμακευτικες φαρμακοτεχνικες μορφες διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
HUP9904092A2 (hu) Gyógyszerkészítmény HIV és rák kezelésére valamint eljárás előállítására
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
CY1105913T1 (el) Νεα τυποποιηση αepολυματος που πepιεχει ενα πολικο φθοριωμενο μοριο
AU2001291678A1 (en) Pharmaceutical compositions
DK0918507T3 (da) Aerosolformuleringer
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
NO2012019I2 (no) Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
RU94046149A (ru) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
ATE297203T1 (de) Antithrombotische mitteln
CL2008003324A1 (es) Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
SE0101932D0 (sv) Pharmaceutical combinations
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
MX2022008191A (es) Soluciones orales que comprenden sales de lisdexanfetamina.
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
EA200601578A1 (ru) Стабильные фармацевтические растворы для дозированных ингаляторов под давлением
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
AR057885A1 (es) Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas.
ES2123137T3 (es) Procedimiento para la preparacion de derivados de ester de aminofosfonato azamacrociclico a aciclico.
UY27461A1 (es) Formas pseudopolimorficas de cardevilol.